Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
11 pending office actions • 7 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Research Development Foundation has 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 10 distinct examiners, meaning each examiner is currently reviewing a case for the foundation. The active prosecution is spread across 6 distinct art units, reflecting a technical focus within the biotechnology sector.
LAU, MICHAEL J is the busiest examiner for the portfolio, with 1 pending office action currently assigned. Since there are 10 pending office actions in total, the workload is spread across the 10 distinct examiners. The involvement of 6 distinct art units means the legal team must adapt to the specific examination styles of multiple different groups. This structure, where 10 distinct examiners each handle one of the 10 pending office actions, ensures that no single examiner's personal tendencies have a disproportionate impact on the foundation's overall patenting success in the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §112 only | 2 (18%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 5 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, MICHAEL J | 1 | 72.0% | +23.4% |
| ARIANI, KADE | 1 | 74.9% | +32.4% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.1% | +39.3% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
| FAN, LYNN Y | 1 | 47.3% | +49.5% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
| ANJARIA, SHREYA PARAG | 1 | 53.7% | +26.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998194 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | OGUNBIYI, OLUWATOSIN A | 36d overdue |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | BUTTICE, AUDREY L | 28d overdue |
| 18248739 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | BEHARRY, ZANNA MARIA | 19d overdue |
| 18980005 | SYSTEMS AND METHODS FOR CORONARY OCCLUSION TREATMENT | LAU, MICHAEL J | — |
| 17611315 | METHODS AND APPARATUS FOR HIGH-SPEED AND HIGH-ASPECT RATIO LASER SUBTRACTIVE MATERIAL PROCESSING | FEDORKY, MEGAN TAYLOR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17548467 | SYSTEMS AND METHODS FOR LASER-INDUCED CALCIUM FRACTURES | ANJARIA, SHREYA PARAG | 134d overdue |
| 18060134 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF BONE DISORDERS | FAN, LYNN Y | 79d overdue |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | LI, RUIXIANG | 77d overdue |
| 17998194 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | OGUNBIYI, OLUWATOSIN A | 36d overdue |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | BUTTICE, AUDREY L | 28d overdue |
| 18248739 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | BEHARRY, ZANNA MARIA | 19d overdue |
| 18060183 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | NOBLE, MARCIA STEPHENS | 17d overdue |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | PAGUIO FRISING, MICHELLE F | 84d |
| Art Unit | Apps |
|---|---|
| 1651 | 2 |
| 1632 | 2 |
| 3796 | 2 |
| 1647 | 1 |
| 1759 | 1 |
| 1645 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18980005 | SYSTEMS AND METHODS FOR CORONARY OCCLUSION TREATMENT | LAU, MICHAEL J | — | §103§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18619514 | COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES | ARIANI, KADE | 1651 | §103§112DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | PAGUIO FRISING, MICHELLE F | 1651 | §103DP | Non-Final OA | 84d | Pending | Jan 16, 2024 |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 28d overdue | Pending | Jun 09, 2023 |
| 18248739 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | BEHARRY, ZANNA MARIA | 1632 | §103§112Other | Final Rejection | 19d overdue | Pending | Apr 12, 2023 |
| 18060183 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | NOBLE, MARCIA STEPHENS | 1632 | §112 | Final Rejection | 17d overdue | Pending | Nov 30, 2022 |
| 18060134 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF BONE DISORDERS | FAN, LYNN Y | 1759 | §103 | Non-Final OA | 79d overdue | Pending | Nov 30, 2022 |
| 17998194 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103§112Other | Final Rejection | 36d overdue | Pending | Nov 08, 2022 |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | LI, RUIXIANG | 1674 | §112 | Non-Final OA | 77d overdue | Pending | Nov 03, 2022 |
| 17548467 | SYSTEMS AND METHODS FOR LASER-INDUCED CALCIUM FRACTURES | ANJARIA, SHREYA PARAG | 3796 | §103 | Non-Final OA | 134d overdue | Pending | Dec 10, 2021 |
| 17611315 | METHODS AND APPARATUS FOR HIGH-SPEED AND HIGH-ASPECT RATIO LASER SUBTRACTIVE MATERIAL PROCESSING | FEDORKY, MEGAN TAYLOR | 3796 | §103§112 | Non-Final OA | — | Pending | Nov 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial